1. The production of malignant primary hepatic tumours in the rat by feeding dimethylnitrosamine;Magee;Br J Cancer,1956
2. European Medicines Agency. ICH guideline M7(R1) on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk. EMA/CHMP/ICH/83812/2013. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-assessment-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential_en.pdf. Accessed September 7, 2021.
3. Short commentary on NDMA (N-nitrosodimethylamine) contamination of Valsartan products;Snodin;Regul Toxicol Pharmacol,2019
4. European Medicines Agency. Questions and answers on “Information on nitrosamines for marketing authorisation holders” EMA/CHMP/428592/2019 Rev. 3. 27 March 2020. Available at: https://www.ema.europa.eu/en/documents/referral/nitrosamines-emea-h-a53-1490-questions-answers-information-nitrosamines-marketing-authorisation_en.pdf. Accessed September 7, 2021.
5. Potential for the formation of N-nitrosamines during the manufacture of active pharmaceutical ingredients: an assessment of the risk posed by trace nitrite in water;Ashworth;Org Process Res Dev,2020